Investigators have tested whether combination immunotherapy, targeting both co-inhibitory and co-stimulatory molecules, is capable of overcoming tumor immune tolerance to induce a potent CD8 T cell response and ultimately tumor regression. Here, CD8A is linked to neoplasm.